View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports

Next: 2 directors

Two Directors at Next sold 57,588 shares at between 10,985p and 10,987p. The significance rating of the trade was 92/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years ...

Andreas Riemann
  • Andreas Riemann
ING Helpdesk
  • ING Helpdesk

Benelux Morning Notes

B&S Group: FY24 results and FY25 outlook in line. UCB: Peer Incyte fails to impress in Hidradenitis Suppurativa

 PRESS RELEASE

EQS-News: Allgeier SE: Klarstellung zum Prüfungsergebnis der BaFin

EQS-News: ALLGEIER SE / Schlagwort(e): Stellungnahme Allgeier SE: Klarstellung zum Prüfungsergebnis der BaFin 11.03.2025 / 08:51 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. München, 11.03.2025 – Die Bundesanstalt für Finanzdienstleistungsaufsicht (BaFin) hat am gestrigen Tag das Ergebnis ihrer am 12. Juli 2022 angekündigten Prüfung betreffend den Konzernabschluss der Allgeier SE (ISIN DE000A2GS633, WKN A2GS63) zum 31. Dezember 2020 veröffentlicht. Der Vorstand der Allgeier SE möchte dazu folgendes erläutern und klarstellen: Die v...

 PRESS RELEASE

EQS-News: Allgeier SE: Clarification on the BaFin audit result

EQS-News: ALLGEIER SE / Key word(s): Statement Allgeier SE: Clarification on the BaFin audit result 11.03.2025 / 08:51 CET/CEST The issuer is solely responsible for the content of this announcement. Munich, 11 March 2025 – Yesterday, the German Federal Financial Supervisory Authority (BaFin) published the results of its audit, announced on July 12, 2022, on the consolidated financial statements of Allgeier SE (ISIN DE000A2GS633, WKN A2GS63) as of December 31, 2020. With regard to this, the Management Board of Allgeier SE would like to explain and clarify the following: T...

ING Helpdesk
  • ING Helpdesk

Benelux Morning Notes

B&S Group: Preview - meeting its guidance. Randstad: Highlights of corporate roadshow. Staffing: US temp volume trend stable but still soft in Feb; upward revisions to Jan/Dec. Vopak: Ahead of its CMD

 PRESS RELEASE

EQS-News: Evotec gibt wichtige Fortschritte in der Neurologie-Partners...

EQS-News: Evotec SE / Schlagwort(e): Sonstiges Evotec gibt wichtige Fortschritte in der Neurologie-Partnerschaft mit Bristol Myers Squibb bekannt 04.03.2025 / 07:30 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich.   Laufende strategische Partnerschaft bringt gemeinsame Pipeline in der  Neurodegenerationsforschung voran Evotec erhält eine Zahlung von 20 Millionen Dollar, um die Forschung weiter voranzutreiben   Hamburg, 04 März 2025: Evotec SE (Frankfurter Wertpapierbörse: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: ...

 PRESS RELEASE

EQS-News: Evotec Announces Key Progress in Neuroscience Collaboration ...

EQS-News: Evotec SE / Key word(s): Miscellaneous Evotec Announces Key Progress in Neuroscience Collaboration with Bristol Myers Squibb 04.03.2025 / 07:30 CET/CEST The issuer is solely responsible for the content of this announcement.   Ongoing strategic partnership advances joint pipeline in neurodegeneration research Evotec receives a $20 million payment to further progress research   Hamburg, Germany, 04 March 2025: Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced another major accomplishment in it...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch